

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-6. (Canceled)

7. (Currently Amended) ~~The liposomal formulation of claim 6~~ A liposomal formulation comprising:

- a) a liposome having an antineoplastic drug encapsulated therein; and
- b) an empty liposome, wherein said antineoplastic drug is a camptothecin.

8. (Original) The liposomal formulation of claim 7, wherein said camptothecin is a member selected from the group consisting of irinotecan, topotecan, 9-amino camptothecin, 10,11-methylenedioxy camptothecin, 9-nitro camptothecin, TAS 103, 7-(4-methyl-piperazino-methylene)-10, 11-ethylenedioxy-20(S)-camptothecin and 7-(2-N-isopropylamino)ethyl-20(S)-camptothecin.

9. (Original) The liposomal formulation of claim 8, wherein said camptothecin is topotecan.

10. (Currently Amended) ~~The liposomal formulation of claim 9~~ A liposomal formulation comprising:

- a) a liposome having an antineoplastic drug encapsulated therein; and
- b) an empty liposome, wherein said antineoplastic drug is a vinca alkaloid.

11. (Original) The liposomal formulation of claim 10, wherein said vinca alkaloid is a member selected from the group consisting of vincristine, vinblastine, vinorelbine and vindesine.

12. (Original) The liposomal formulation of claim 11, wherein said vinca alkaloid is vincristine.

13. (Original) The liposomal formulation of claim 11, wherein said vinca alkaloid is vinorelbine.

14-16. (Canceled)

17. (Currently Amended) A liposomal formulation comprising:

a) a liposome having an active agent encapsulated therein; and

b) an empty liposome~~The liposomal formulation of claim 1,~~ wherein said active agent comprises free active agent and precipitated active agent.

18. (Original) The liposomal formulation of claim 17, wherein at least 50% of said active agent is precipitated active agent.

19-20. (Canceled)

21. (Currently Amended) ~~The liposomal formulation of claim 20~~ A liposomal formulation comprising:

a) a liposome having an active agent encapsulated therein; and

b) an empty liposome, wherein the said liposomes comprise sphingomyelin and cholesterol are present at a molar ratio from 75/25 mol%/mol% sphingomyelin/cholesterol to 30/50 mol%/mol% sphingomyelin/cholesterol.

22. (New) The liposomal formulation of claim 17, wherein said active agent is an antineoplastic drug.

23. (New) The liposomal formulation of claim 22, wherein said antineoplastic drug is a camptothecin.

24. (New) The liposomal formulation of claim 23, wherein said camptothecin is a member selected from the group consisting of irinotecan, topotecan, 9-amino camptothecin, 10,11-methylenedioxy camptothecin, 9-nitro camptothecin, TAS 103, 7-(4-methyl-piperazino-methylene)-10, 11-ethylenedioxy-20(S)-camptothecin and 7-(2-N-isopropylamino)ethyl)-20(S)-camptothecin.

25. (New) The liposomal formulation of claim 24, wherein said camptothecin is topotecan.

26. (New) The liposomal formulation of claim 22, wherein said antineoplastic drug is a vinca alkaloid.

27. (New) The liposomal formulation of claim 26, wherein said vinca alkaloid is a member selected from the group consisting of vincristine, vinblastine, vinorelbine and vindesine.

28. (New) The liposomal formulation of claim 27, wherein said vinca alkaloid is vincristine.

29. (New) The liposomal formulation of claim 27, wherein said vinca alkaloid is vinorelbine.